Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...

Autolus Therapeutics received acceptance for an oral presentation and three poster presentations at the prestigious 2025 Tandem Meetings, highlighting their commitment to disseminating research ...

LONDON - Autolus Therapeutics plc (NASDAQ:AUTL), a biopharmaceutical company specializing in T cell therapies for cancer, has announced its participation in the upcoming 2025 Tandem Meetings | ...

1 Day AUTL -1.35% DJIA 1.24% Russell 2K 1.85% Health Care/Life Sciences -1.75% ...

Avanza Fonder AB bought a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL – Free Report) during the fourth quarter, according to its most recent filing with the SEC.The fund ...

Autolus Therapeutics plc (NASDAQ:AUTL – Get Free Report) rose 5% during trading on Tuesday .The company traded as high as $2.33 and last traded at $2.32. Approximately 204,897 shares traded ...

In a report released today, Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target ...

European equities traded in the US as American depositary receipts were advancing on Thursday morning, up 0.5% to 1,346.74 on the S&P Europe Select ADR Index. From continental Europe, the gainers were ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

LONDON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell ...

LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed ...